title: [Indications and limits of cefotaxime monotherapy].
abstract: Single drug therapy using a third generation cephalosporin of the cefotaxime type is possible in a number of situations where host defenses are intact, the causative microorganism is very sensitive (MIC less than 1 mg/l) and not concerned with phenomena of resistance by mutation, and the antibiotic is able to reach the site of infection at high concentrations. In contrast, the indications for two-drug therapy including an aminoglycoside appear to be better identified in patients with granulocytopenia. The possibility of single drug therapy preceded by a short period of two-drug therapy is also discussed.
mesh_terms: D001419:Bacteria / Q000187:drug effects; D002439:Cefotaxime / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006069:Gonorrhea / Q000188:drug therapy; D006801:Humans; D008581:Meningitis / Q000188:drug therapy; D011018:Pneumonia, Pneumococcal / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy
chemical_list: D002439:Cefotaxime
vernacular_title: Indications et limites de la monothérapie par le céfotaxime.